ZA99369B - N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)-acetoxyl]-L-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1-beta converting enzyme (ICE). - Google Patents

N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)-acetoxyl]-L-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1-beta converting enzyme (ICE).

Info

Publication number
ZA99369B
ZA99369B ZA9900369A ZA99369A ZA99369B ZA 99369 B ZA99369 B ZA 99369B ZA 9900369 A ZA9900369 A ZA 9900369A ZA 99369 A ZA99369 A ZA 99369A ZA 99369 B ZA99369 B ZA 99369B
Authority
ZA
South Africa
Prior art keywords
interleukin
converting enzyme
acetoxyl
benzyloxycarbonyl
pyrimidinyl
Prior art date
Application number
ZA9900369A
Other languages
English (en)
Inventor
Gerald Paul Schielke
Aurash Shahripour
Original Assignee
Warner Lambert Co
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Basf Ag filed Critical Warner Lambert Co
Publication of ZA99369B publication Critical patent/ZA99369B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA9900369A 1998-01-20 1999-01-19 N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)-acetoxyl]-L-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1-beta converting enzyme (ICE). ZA99369B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7191898P 1998-01-20 1998-01-20

Publications (1)

Publication Number Publication Date
ZA99369B true ZA99369B (en) 1999-07-20

Family

ID=22104428

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900369A ZA99369B (en) 1998-01-20 1999-01-19 N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)-acetoxyl]-L-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1-beta converting enzyme (ICE).

Country Status (11)

Country Link
EP (1) EP1049703B1 (xx)
JP (1) JP2002509153A (xx)
AT (1) ATE232536T1 (xx)
AU (1) AU1466399A (xx)
CA (1) CA2309546A1 (xx)
DE (1) DE69811404T2 (xx)
DK (1) DK1049703T3 (xx)
ES (1) ES2193589T3 (xx)
PT (1) PT1049703E (xx)
WO (1) WO1999036426A1 (xx)
ZA (1) ZA99369B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
DE60108948T2 (de) 2000-04-05 2005-11-03 Pharmacia Corp. Polyzyclisch aryl und heteroaryl substituierte 4-pyronen verwendbar als selektive hemmung von dem koagulationsprozess
EP1268428A2 (en) 2000-04-05 2003-01-02 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
CA2405684A1 (en) 2000-04-17 2001-10-25 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001222501A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US6943173B2 (en) 2000-07-18 2005-09-13 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
JP2004517074A (ja) 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク. Opglへの抗体
EP1432687A2 (en) 2001-10-03 2004-06-30 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
EP1438292A1 (en) 2001-10-03 2004-07-21 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
ES2532433T3 (es) 2004-03-12 2015-03-26 Vertex Pharmaceuticals Incorporated Proceso y productos intermedios para la preparación de inhibidores de la acetal caspasa aspártica
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
CN101268084A (zh) 2005-07-28 2008-09-17 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物
US20140309172A1 (en) 2010-11-05 2014-10-16 Dagmar Ringe Ice inhibiting compounds and uses thereof
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
CA2186511C (en) * 1994-03-31 2009-02-10 Roland E. Dolle Pyrimidinyl derivatives as interleukin inhibitors

Also Published As

Publication number Publication date
DK1049703T3 (da) 2003-06-02
ATE232536T1 (de) 2003-02-15
EP1049703B1 (en) 2003-02-12
WO1999036426A1 (en) 1999-07-22
JP2002509153A (ja) 2002-03-26
EP1049703A1 (en) 2000-11-08
AU1466399A (en) 1999-08-02
ES2193589T3 (es) 2003-11-01
CA2309546A1 (en) 1999-07-22
PT1049703E (pt) 2003-06-30
DE69811404T2 (de) 2003-12-04
DE69811404D1 (de) 2003-03-20

Similar Documents

Publication Publication Date Title
ZA99369B (en) N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)-acetoxyl]-L-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1-beta converting enzyme (ICE).
NO991674D0 (no) Interleukin-1<Beta>omdannelsesenzym-inhibitor-sulfonamider
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
DK1240165T3 (da) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamid-inhibitorer af cyclinafhængige kinaser
HU9602664D0 (en) Pyrimidinyl derivatives as interleukin inhibitors
MX9606546A (es) Compuestos inhibidores de la enzima conversiva de interleukina-1 beta.
BR9709514A (pt) Processo e composições úteis para a inibição de angiogénese mediada por alfa beta
BG107468A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
MY125768A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
IL129124A0 (en) Sulfonamide substituted aspartic acid interleukin -1beta converting enzyme inhibitors
CA2099867A1 (en) 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
NO20010490D0 (no) Inhibisjon av ''graft-versus-host''-sykdom
LT2003001A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
MA24831A1 (fr) Procede pour la preparation d'acides hydroxamiques
WO1999021005A3 (en) Pharmaceutical grade st. john's wort
DE69902142D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen